Eagle Pharmaceuticals, Inc. (EGRX)
| Market Cap | 7.75M -81.4% |
| Revenue (ttm) | 257.55M -5.4% |
| Net Income | 11.95M -47.6% |
| EPS | 0.91 -48.4% |
| Shares Out | 13.02M |
| PE Ratio | 0.65 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.5950 |
| Previous Close | 0.1050 |
| Day's Range | 0.5950 - 0.5950 |
| 52-Week Range | 0.0011 - 3.7250 |
| Beta | 0.64 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the i... [Read more]
Full Company ProfileNews
Did Eagle Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Eagle Pharmaceuticals announces divestiture of Barhemsys
Eagle Pharmaceuticals (EGRX) announced the divestiture of the marketing authorization for Barhemsys in the U.S. to LXO Group, Paris, France. Barhemsys is used for the treatment of Postoperative Nausea...
Eagle Pharmaceuticals Announces Divestiture of Barhemsys
WOODCLIFF LAKE, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the divestiture of the marketing authorization for...
HALPER SADEH LLC ENCOURAGES EAGLE PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investi...
Halper Sadeh LLC Encourages Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Eagle Pharmaceuticals, Inc. (OTCPK: EGRX) breached their fiduciary ...
Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements
WOODCLIFF LAKE, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company's unaudited financial statements for the...
Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements
WOODCLIFF LAKE, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company's unaudited financial statements for the...
Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years
WOODCLIFF LAKE, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced the availability of proxy materials for its 2025 Annual ...
Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors
WOODCLIFF LAKE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has agreed to appoint Abhinav “Abi” Jain as an in...
Eagle Pharmaceuticals Announces 2025 Annual Meeting Date
WOODCLIFF LAKE, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its 2025 Annual Meeting of Stockholders (the “2025 A...
Eagle Pharmaceuticals announces $69M pact to monetize Bendeka royalties
Eagle Pharmaceuticals (EGRX) announced that it has entered into a royalty purchase agreement with an entity that was provided capital by funds managed by Blue Owl Capital, dated March 31…
Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan
WOODCLIFF LAKE, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has approved a...
Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration
WOODCLIFF LAKE, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq and OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has notified The Nasdaq Stock Market, ...
Eagle Pharmaceuticals appoints Christopher Krawtschuk as CFO
Eagle Pharmaceuticals (EGRX) announced the appointment of Christopher Krawtschuk as CFO of the Company, effective November 11, 2024. In connection with Mr. Krawtschuk’s appointment, Steven Ratoff step...
Eagle Pharmaceuticals adopts limited duration stockholder rights plan
Eagle Pharmaceuticals (EGRX) announced that its Board of Directors has adopted a limited duration stockholder rights agreement, effective immediately. The Company continues to experience a significant...
Union Square Park Capital Management's Strategic Acquisition of Eagle Pharmaceuticals Shares
On October 3, 2024, Union Square Park Capital Management, LLC (Trades, Portfolio) made a significant move in the pharmaceutical sector by acquiring 1,191,490 shares of Eagle Pharmaceuticals Inc (EGRX,...
Eagle Pharmaceuticals says in default under credit agreement
In a regulatory agreement, Eagle Pharmaceuticals said: “Under the terms of the Third Amended and Restated Credit Agreement, dated November 1, 2022, among the Company, the lenders party thereto and…
Eagle Pharmaceuticals delays annual report on Form 10-K filing
In a regulatory filing, Eagle Pharmaceuticals said that on October 1, the company notified the hearings panel of The Nasdaq Stock Market LLC that the company did not anticipate filing…
Eagle Pharmaceuticals commences review to evaluate range of alternatives
The company has commenced a review process to evaluate a range of potential financing and other alternatives to strengthen its liquidity position and capital structure. There is no deadline or…
Eagle Pharmaceuticals sees ‘one or more’ material weaknesses
In a regulatory filing, Eagle Pharmaceuticals said that on September 27, the Audit Committee of the Board of Directors of the company, based on the recommendation of, and after consultation…
Eagle Pharmaceuticals announces receipt of delisting notification from Nasdaq
Eagle Pharmaceuticals “announced that it received a notice on August 21, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC advising the Company that pursuant to Nasdaq…
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
WOODCLIFF LAKE, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company” or “Eagle”) today announced that it received a notice (the “Notice”) on August 21, 202...
Eagle Pharmaceuticals receives delisting notification from Nasdaq
Eagle Pharmaceuticals received a notice on May 20, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market advising the Company that it has initiated a process to delist…
Eagle Pharmaceuticals says unlikely to file Form 10-Q or 10-K by May 13
In a press release after the market close on Friday, Eagle Pharmaceuticals announced that it received a notice on April 8 from the Listing Qualifications Department of The Nasdaq Stock…
Eagle Pharmaceuticals to present data from Phase III trial of amisulpride
Eagle Pharmaceuticals announced that data from the Company’s Phase III trial demonstrating the sustained response of amisulpride for the rescue treatment of postoperative nausea and vomiting will be p...